Strategic Treatment Interruptions During Imatinib Treatment of Chronic Myelogenous Leukemia
暂无分享,去创建一个
Doron Levy | Peter S Kim | Dana Paquin | Dana C. Paquin | D. Levy | P. Kim | Peter P. Lee | Peter P Lee
[1] B. Druker,et al. Chronic myelogenous leukemia , 2001, Current opinion in oncology.
[2] C. Yoshida. [Chronic myelogenous leukemia]. , 2013, [Rinsho ketsueki] The Japanese journal of clinical hematology.
[3] Doron Levy,et al. Dynamics and Potential Impact of the Immune Response to Chronic Myelogenous Leukemia , 2008, PLoS Comput. Biol..
[4] R. Koup. Reconsidering Early HIV Treatment and Supervised Treatment Interruptions , 2004, PLoS medicine.
[5] D. Kirschner,et al. Predicting differential responses to structured treatment interruptions during HAART , 2004, Bulletin of mathematical biology.
[6] J. Cayuela,et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. , 2005, Blood.
[7] M. Gordon. Molecular Responses in Patients With Chronic Myelogenous Leukemia in Chronic Phase Treated With Imatinib MesylateCortes J, Talpaz M, O'Brien S, et al (Univ of Texas MD Anderson Cancer Ctr, Houston) Clin Cancer Res 11:3425–3432, 2005§ , 2006 .
[8] Richard J. Jones,et al. Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant , 2004, Current opinion in oncology.
[9] Susan O'Brien,et al. Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate , 2005, Clinical Cancer Research.
[10] M. D. McKay,et al. A comparison of three methods for selecting values of input variables in the analysis of output from a computer code , 2000 .
[11] Ingo Roeder,et al. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications , 2006, Nature Medicine.
[12] Dominik Wodarz,et al. Drug resistance in cancer: principles of emergence and prevention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[13] J. Reiffers,et al. Persistence of complete molecular remission in chronic myeloid leukemia after imatinib discontinuation: Interim analysis of the STIM trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Tom Lenaerts,et al. Dynamics of chronic myeloid leukemia under nilotinib therapy , 2010 .
[15] B. Löwenberg. Minimal residual disease in chronic myeloid leukemia. , 2003, The New England journal of medicine.
[16] Franziska Michor,et al. Successful Therapy Must Eradicate Cancer Stem Cells , 2006, Stem cells.
[17] F. Andreoni,et al. The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years. , 2006, Blood cells, molecules & diseases.
[18] Stephanie J. Lee. Chronic myelogenous leukaemia. , 2000 .
[19] C. Sawyers. Chronic myeloid leukemia. , 1999, The New England journal of medicine.
[20] I. Glauche,et al. Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia - insights from mathematical model analyses , 2007, Journal of Molecular Medicine.
[21] B. Adams,et al. Dynamic multidrug therapies for hiv: optimal and sti control approaches. , 2004, Mathematical biosciences and engineering : MBE.
[22] Holden T Maecker,et al. Development and dynamics of robust T-cell responses to CML under imatinib treatment. , 2008, Blood.